866-997-4948(US-Canada Toll Free)

MAP Kinase Interacting Serine/Threonine Protein Kinase 2-Pipeline Review, H2 2019

Published By :

Global Markets Direct

Published Date : Nov 2019

Category :

Pharmaceutical

No. of Pages : 53 Pages

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Pipeline Review, H2 2019

Summary

According to the recently published report 'MAP Kinase Interacting SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019'; MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - MAP kinase-interacting serine/threonine-protein kinase 2 is an enzyme encoded by the MKNK2 gene. It phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. It plays a role in the response to environmental stress and cytokines. It appears to regulate translation by phosphorylating EIF4E thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. It triggers EIF4E shuttling from cytoplasm to nucleus. It acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis.

The report 'MAP Kinase Interacting SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Discovery stages are 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Gallbladder Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammation, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Uveal Melanoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Transitional Cell Cancer (Urothelial Cell Cancer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)
- The report reviews MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Overview
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AUM Biosciences Pte Ltd
eFFECTOR Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
Oncodesign SA
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Drug Profiles
AUM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETC-17804452 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Mnk2 for Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKNK1 and MKNK2 for Oncology and Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKNK2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tomivosertib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Dormant Products
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Mar 29, 2019: eFFECTOR Therapeutics to present data on Tomivosertib at AACR 2019 annual meeting
Jan 14, 2019: Research published in Nature Medicine demonstrates the immunological effects of Tomivosertib, including inhibiting production of checkpoint protein PD-L1 and increasing T Cell Infiltration into tumors
Dec 11, 2018: eFFECTOR initiates dosing in phase 2 trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
Jul 27, 2018: eFFECTOR initiates dosing of eFT508 (tomivosertib) in a phase 2 add-on (CPI-A) trial in combination with checkpoint inhibitors to treat patients with insufficient response to checkpoint inhibitors alone
Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkins Lymphoma
May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting
Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics' Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
Dec 05, 2017: Oncodesign Reports Positive Results for Its MNK1/2 Program
Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017
Apr 10, 2017: Cancer Genetics is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AUM Biosciences Pte Ltd, H2 2019
Pipeline by eFFECTOR Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Oncodesign SA, H2 2019
Dormant Projects, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Route of Administration, H2 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *